Utama › Kanser Ovari › Georgia
Kajian klinikal Kanser Ovari di Georgia
35 kajian untuk Kanser Ovari sedang mencari peserta di lokasi di Georgia.
Bandar di Georgia
Teks kajian rasmi (Bahasa Inggeris)
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Emory University, Atlanta
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06465069A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Winship Cancer Institute of Emory University, Atlanta
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06270706A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Emory Winship Cancer Institute, Atlanta
- Augusta University, Augusta
Mengambil pesertaFasa 1
Umur 19 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06586957A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Site 0108 - Emory University Hospital, Atlanta
Mengambil pesertaFasa 2
Umur 18 ke atas · Wanita · Dikemas kini 29 Sep 2026 · NCT05128825Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- Piedmont Healthcare, Atlanta
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Wanita · Dikemas kini 29 Sep 2026 · NCT05051722A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Winship Cancer Institute, Emory University, Atlanta
- Nancy N. & J.C. Lewis Cancer and Research Pavillion, Savannah
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07213804A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Winship Cancer Institute of Emory University ( Site 0037), Atlanta
Mengambil pesertaFasa 3
Umur 18 ke atas · Wanita · Dikemas kini 17 Sep 2026 · NCT07318558A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Northeast Georgia Medical Center Gainesville, Gainesville
Mengambil pesertaFasa 2
Umur 18 hingga 99 · Wanita · Dikemas kini 15 Sep 2026 · NCT07023627Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Winship Cancer Institute At Emory University, Atlanta
- Georgia Cancer Center, Augusta
Mengambil pesertaFasa 3
Umur 18 ke atas · Wanita · Dikemas kini 15 Sep 2026 · NCT07214779FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- Emory University, Atlanta
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Sep 2026 · NCT06303505Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Georgia Cancer Center at Augusta University, Augusta
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Sep 2026 · NCT06293898A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- Emory University, Atlanta
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Sep 2026 · NCT06400472A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Winship Cancer Institute of Emory University ( Site 0086), Atlanta
- Augusta University - Georgia Cancer Center ( Site 0066), Augusta
Mengambil pesertaFasa 3
Umur 18 ke atas · Wanita · Dikemas kini 3 Sep 2026 · NCT06824467Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- Emory University - Winship Cancer Institute, Atlanta
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 27 Ogo 2026 · NCT06582017Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
Mengambil pesertaFasa 2
Umur 18 ke atas · Wanita · Dikemas kini 27 Ogo 2026 · NCT06492070Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- Emory University, Atlanta
Mengambil pesertaFasa 3
Umur 18 ke atas · Wanita · Dikemas kini 26 Ogo 2026 · NCT05281471Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- Winship Cancer Institute, Emory University, Atlanta
Mengambil pesertaFasa 1
Umur 15 ke atas · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT06276491Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
Mengambil pesertaFasa 1/2
12 Months – 30 Years · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT04851119Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 19 Ogo 2026 · NCT07001748A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- dan 4 lagi
Mengambil peserta
Umur 35 hingga 50 · Wanita · Dikemas kini 7 Ogo 2026 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- dan 4 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Ogo 2026 · NCT06580314Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Augusta University Georgia Cancer Center, Augusta
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Ogo 2026 · NCT05579366Clinical Pre-screening Protocol for Ovarian Cancer
- Emory Winship Cancer Institute, Atlanta
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Wanita · Dikemas kini 30 Jul 2026 · NCT03877796First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Winship Cancer Institute, Emory University, Atlanta
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Jul 2026 · NCT05768139Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Nancy N. & J.C Lewis Cancer & Research Pavillion- St. Josephs/ Candler Health System, Savannah
Mengambil pesertaFasa 3
Umur 18 ke atas · Wanita · Dikemas kini 2 Jul 2026 · NCT06819007A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Winship Cancer Institute, Emory University, Atlanta
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Jun 2026 · NCT05377996A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
- GSK Investigational Site, Atlanta
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Jun 2026 · NCT04641247A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- Georgia Cancer Center, Augusta
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Jun 2026 · NCT04300556Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics
- Emory University Hospital/Winship Cancer Institute, Atlanta
Mengambil pesertaSukarelawan sihat dialu-alukan
Umur 25 ke atas · Wanita · Dikemas kini 26 Mei 2026 · NCT06760507DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- USA10-0, Atlanta
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Mei 2026 · NCT06953089Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
- Emory Winship Cancer Institute, Atlanta
- Georgia Cancer Center at Augusta University, Augusta
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Apr 2026 · NCT05735080cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- North Georgia Health System, Gainesville
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 ke atas · Semua jantina · Dikemas kini 20 Jan 2026 · NCT05366881CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
- Winship Cancer Institute, Emory University, Atlanta
Mengambil pesertaFasa 2
Umur 18 ke atas · Wanita · Dikemas kini 23 Dis 2025 · NCT06690775SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Atlanta
- Massive Bio SYNERGY-AI site, Savannah
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774A Beta-only IL-2 ImmunoTherapY Study
- Emory - Winship Cancer Institute, Atlanta
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Jul 2025 · NCT05086692Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.